Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis.
Pozniak
A
A
Department of Genitourinary Medicine, Kings Health Care NHS Trust, London, UK.
Nelson
M R
MR
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000009:adverse effects* / Q000191:economics; D017963:Azithromycin / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D017828:Rifabutin / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017828:Rifabutin; D017963:Azithromycin; D017291:Clarithromycin